Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Related Articles by Review for PubMed (Select 14517171)

1.

Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels.

Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, Burke S, Shoukas AA, Nyhan D, Champion HC, Hare JM.

Circulation. 2003 Oct 21;108(16):2000-6. Epub 2003 Sep 29.

2.

Arginase and vascular aging.

Santhanam L, Christianson DW, Nyhan D, Berkowitz DE.

J Appl Physiol (1985). 2008 Nov;105(5):1632-42. doi: 10.1152/japplphysiol.90627.2008. Epub 2008 Aug 21. Review.

3.

Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization.

Boucher JL, Moali C, Tenu JP.

Cell Mol Life Sci. 1999 Jul;55(8-9):1015-28. Review.

PMID:
10484661
4.

Endothelial arginase: a new target in atherosclerosis.

Yang Z, Ming XF.

Curr Hypertens Rep. 2006 Apr;8(1):54-9. Review.

PMID:
16600160
5.

Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.

Sydow K, Mondon CE, Cooke JP.

Vasc Med. 2005 Jul;10 Suppl 1:S35-43. Review.

PMID:
16444867
6.
7.

Arginase: a critical regulator of nitric oxide synthesis and vascular function.

Durante W, Johnson FK, Johnson RA.

Clin Exp Pharmacol Physiol. 2007 Sep;34(9):906-11. Review.

8.

Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?

Pernow J, Jung C.

Cardiovasc Res. 2013 Jun 1;98(3):334-43. doi: 10.1093/cvr/cvt036. Epub 2013 Feb 14. Review.

9.

Arginase in glomerulonephritis.

Waddington SN.

Kidney Int. 2002 Mar;61(3):876-81. Review.

10.

Is atherosclerosis an arginine deficiency disease?

Cooke JP.

J Investig Med. 1998 Oct;46(8):377-80. Review.

PMID:
9805422
11.

Development of novel arginase inhibitors for therapy of endothelial dysfunction.

Steppan J, Nyhan D, Berkowitz DE.

Front Immunol. 2013 Sep 17;4:278. doi: 10.3389/fimmu.2013.00278. Review.

12.

Beneficial circulatory effect of L-arginine.

Nakaki T, Kato R.

Jpn J Pharmacol. 1994 Oct;66(2):167-71. Review.

13.

[Perspectives of pharmacological correction of nitroxidergic vasorelaxation in subarachnoidal hemorrhage].

Karpiuk VB, Shubich MG.

Zh Vopr Neirokhir Im N N Burdenko. 2002 Apr-Jun;(2):56-61. Review. Russian.

PMID:
12214511
14.

Endothelial dysfunction in hypertension: the role of arginase.

Michell DL, Andrews KL, Chin-Dusting JP.

Front Biosci (Schol Ed). 2011 Jun 1;3:946-60. Review.

PMID:
21622244
15.

I. Arginine.

Tapiero H, Mathé G, Couvreur P, Tew KD.

Biomed Pharmacother. 2002 Nov;56(9):439-45. Review.

PMID:
12481980
16.

Cellular and molecular mechanisms of endothelial cell dysfunction.

Harrison DG.

J Clin Invest. 1997 Nov 1;100(9):2153-7. Review. No abstract available.

17.

Endothelial dysfunction in chronic heart failure: some new basic mechanisms.

Bachetti T.

Ital Heart J. 2000 Oct;1(10):656-61. Review.

PMID:
11061361
18.

Arginine de novo and nitric oxide production in disease states.

Luiking YC, Ten Have GA, Wolfe RR, Deutz NE.

Am J Physiol Endocrinol Metab. 2012 Nov 15;303(10):E1177-89. doi: 10.1152/ajpendo.00284.2012. Epub 2012 Sep 25. Review.

19.

Arginase in retinopathy.

Narayanan SP, Rojas M, Suwanpradid J, Toque HA, Caldwell RW, Caldwell RB.

Prog Retin Eye Res. 2013 Sep;36:260-80. doi: 10.1016/j.preteyeres.2013.06.002. Epub 2013 Jul 3. Review.

20.

[Discovery and significance of NO].

Hirata K, Yokoyama M.

Nihon Rinsho. 2004 Sep;62 Suppl 9:441-5. Review. Japanese. No abstract available.

PMID:
15506423
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk